A61K 39/21
Retroviridae
Official title: Retroviridae, e.g. equine infectious anemia virus
A61K39/21 (Retroviridae) appears on 1,032 US grants and 1,637 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,032
- Published applications
- 1,637
- Assignees
- 699
- Inventors
- 2,421
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 21 | 0 |
| 1999 | 18 | 0 |
| 2000 | 17 | 0 |
| 2001 | 13 | 6 |
| 2002 | 23 | 39 |
| 2003 | 18 | 55 |
| 2004 | 13 | 72 |
| 2005 | 14 | 70 |
| 2006 | 26 | 73 |
| 2007 | 20 | 50 |
| 2008 | 21 | 69 |
| 2009 | 37 | 71 |
| 2010 | 34 | 88 |
| 2011 | 32 | 78 |
| 2012 | 43 | 78 |
| 2013 | 31 | 62 |
| 2014 | 49 | 75 |
| 2015 | 57 | 85 |
| 2016 | 49 | 97 |
| 2017 | 74 | 74 |
| 2018 | 76 | 68 |
| 2019 | 58 | 74 |
| 2020 | 54 | 56 |
| 2021 | 52 | 61 |
| 2022 | 42 | 57 |
| 2023 | 29 | 48 |
| 2024 | 37 | 51 |
| 2025 | 21 | 37 |
| 2026 | 28 | 43 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use29 Sep 2026US 12,747,270 B2Twilight Bioscience, Inc.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Modified envelope protein of human immunodeficiency virus and use thereof4 Aug 2026US 12,697,383 B2Xiamen Innovax Biotech Co., Ltd.
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Improved expression of surface-displayed antigens1 Oct 2026US 2026/0295030 A1Inprother Aps
- Improved alum-anchored immunogens1 Oct 2026US 2026/0295039 A1Massachusetts Institute of Technology
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Hiv vaccine24 Sep 2026US 2026/0284176 A1
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Genetic immunization137US 5,817,637 AThe Trustees of the University of Pennsylvania · 1998